Analyst Research

Report Title Price
Thomson Reuters Stock Report - VALEANT PHARMACEUTICALS INTERNATIONAL INC (VRX-N)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Trading Report for (VRX). A detailed report, including free correlated market analysis, and updates.
Provider: Stock Traders Daily
$58.00
Buy
Valeant Pharmaceuticals Intl
Provider: S&P Capital IQ – STARS Reports
$115.00
Buy
VALEANT PHARMACEUTICALS INTL (VRX) 12-months forecast
Provider: Pechala's Reports
$15.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Valeant Pharmaceuticals International Inc Raises FY 2012 EPS Guidance; Reaffirms FY 2012 Revenue Guidance


Thursday, 2 Aug 2012 07:09am EDT 

Valeant Pharmaceuticals International Inc updated fiscal 2012 guidance and increased cash EPS to $4.55 to $4.75 (or $4.18 to $4.38 excluding one-time items) in fiscal 2012, up from prior guidance of $4.45 to $4.70, and maintained prior guidance of total revenue in the range of $3.4 to $3.6 billion and adjusted cash flow from operations of greater than $1.4 billion. 

Latest Developments for Valeant Pharmaceuticals International Inc

Latest Key Developments in Pharmaceuticals

Company Quote

Valeant Pharmaceuticals International Inc
(VRX.N)
75.38
-2.79 -3.57%
4:02pm EDT